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The apicomplexan parasite Cryptosporidium is a leading global
cause of severe diarrheal disease and an important contributor
to early-childhood mortality. Waterborne outbreaks occur fre-
quently, even in countries with advanced water treatment capa-
bilities, and there is currently no fully effective treatment. Nucleotide
pathways are attractive targets for antimicrobial development,
and several laboratories are designing inhibitors of these enzymes
as potential treatment for Cryptosporidium infections. Here we
take advantage of newly available molecular genetics for Crypto-
sporidium parvum to investigate nucleotide biosynthesis by di-
rected gene ablation. Surprisingly, we found that the parasite
tolerates the loss of classical targets including dihydrofolate
reductase-thymidylate synthase (DHFR-TS) and inosine monophos-
phate dehydrogenase (IMPDH). We show that thymidine kinase
provides a route to thymidine monophosphate in the absence of
DHFR-TS. In contrast, only a single pathway has been identified for
C. parvum purine nucleotide salvage. Nonetheless, multiple en-
zymes in the purine pathway, as well as the adenosine trans-
porter, can be ablated. The resulting mutants are viable under
normal conditions but are hypersensitive to inhibition of purine
nucleotide synthesis in their host cell. Cryptosporidium might use
as-yet undiscovered purine transporters and salvage enzymes;
however, genetic and pharmacological experiments led us to con-
clude that Cryptosporidium imports purine nucleotides from the
host cell. The potential for ATP uptake from the host has signifi-
cant impact on our understanding of parasite energy metabolism
given that Cryptosporidium lacks oxidative phosphorylation and
glycolytic enzymes are not constitutively expressed throughout the
parasite life cycle.
parasite | purine | Cryptosporidium | diarrhea | nucleotide
The protozoan parasite Cryptosporidium is one of the mostimportant infectious causes of diarrheal disease. Large-scale
epidemiological studies linked Cryptosporidium hominis and
parvum infection with severe disease and death in small children
(1), but also found significant adverse effects in milder cases (2).
Cryptosporidium infection has a complex and profound interac-
tion with early-childhood malnutrition, a key risk factor for and a
potentially lasting consequence of this parasite infection (3, 4).
Currently neither fully effective drug treatments nor prophylactic
vaccines are available (3, 5). The parasite invades enterocytes in
the apical brush border of the intestinal tract, where it develops a
set of unique cellular structures, including a pedestal formed
with host cell actin and a membranous feeder organelle thought
to provide access to host metabolites.
Cryptosporidium is a member of the phylum Apicomplexa,
which includes Plasmodium and Toxoplasma, the causes of malaria
and opportunistic and congenital infection, respectively. Compar-
ing the genome of C. parvum with that of Plasmodium falciparum
or Toxoplasma gondii reveals dramatic gene loss (6). C. parvum has
a diminutive genome (9 Mbp) encoding about 3,500 genes. Me-
tabolism is one important aspect of parasite biology that experienced
loss and streamlining in C. parvum. This parasite lost the apico-
plast, a chloroplast-like organelle responsible for the synthesis of
isoprenoids, fatty acids, and heme (7). While a mitochondrion is
still present, it has lost its genome along with the tricarboxylic acid
(TCA) cycle and oxidative phosphorylation. Curiously, glycolytic
enzymes are not constitutively expressed throughout the parasite
life cycle, suggesting a differentiated energy metabolism that is not
fully understood (8). Beyond these organellar functions, C. par-
vum has also lost numerous anabolic pathways typically localized
to the cytoplasm. C. parvum’s core metabolic map (9) is remark-
ably similar to the minimal sets found in obligate intracellular
bacteria like Chlamydia and Rickettsia, parasites that make very
little on their own but instead commandeer from the host.
This metabolic minimalism suggested that the remaining path-
ways and enzymes are essential to the growth of the organism and
thus promising targets for drug development. The recent advent of
CRISPR/Cas9–based genome engineering for Cryptosporidium
(10) allowed us to put this hypothesis to a rigorous experimental
test. Here we use gene targeting to disrupt multiple enzymes in the
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parasite’s purine and pyrimidine nucleotide pathways, two of
which, dihydrofolate reductase-thymidylate synthase (DHFR-TS)
(11) and inosine monophosphate dehydrogenase (IMPDH) (12),
are currently pursued as targets for the treatment of cryptospo-
ridiosis. Loss of these enzymes comes without apparent fitness
cost, but renders the parasites keenly dependent on host cell
nucleotide synthesis. Using inhibitors and tracers, we probe this
metabolic host–parasite relationship and conclude that C. parvum
imports purine nucleotides. This finding has far-reaching conse-
quences in that it suggests that C. parvum could be an energy
parasite.
Results and Discussion
C. parvum Tolerates Loss of Dihydrofolate Reductase-Thymidylate
Synthase. In plants and many protists, dihydrofolate reductase
(DHFR) and thymidylate synthase (TS) are encoded by a single
gene resulting in the expression of a fused dual-activity enzyme
(DHFR-TS). Thymidylate synthase is the dominant user of re-
duced tetrahydrofolate and therefore this arrangement may allow
for substrate channeling and/or coordinated expression of 2 im-
portant cell cycle-regulated enzymes (13). In P. falciparum and T.
gondii, DHFR-TS activity is required for growth and the DHFR
domain is a clinically validated drug target. In contrast, C. parvum
is resistant to antifolate treatment and we have suggested that the
horizontal gene transfer of a thymidine kinase (TK) might have
rendered DHFR-TS dispensable (10, 14). To directly test this
hypothesis, we targeted the DHFR-TS locus for ablation in C.
parvum. Sporozoites were electroporated with a plasmid express-
ing Cas9 and a U6 promoter-driven guide RNA designed to
produce a double-strand break in the middle of the DHFR-TS–
coding region. A DNA cassette encoding a NanoLuciferase-
neomycin resistance (Nluc-Neo) marker flanked by 1,000 bp
matching the up- and downstream sequences of the DHFR-TS
gene was targeted to the locus for replacement of the endog-
enous gene by homologous double cross-over (Fig. 1A). Interferon
(IFN) γ knockout mice were infected with transfected sporozoites,
and paromomycin was provided as a selection agent in the
drinking water of the mice. Luciferase-positive oocysts were ap-
parent 9 days postinfection (SI Appendix, Fig. S1) and were pas-
saged continuously through multiple sets of mice under continued
selection, producing infection and oocyst shedding. We mapped
the DHFR-TS locus of wild-type (WT) andΔDHFR-TS–modified
parasites using PCR of genomic DNA extracts and multiple
primer sets. Amplicons are consistent with a double homologous
cross-over at the 5′ and 3′ ends of the gene and most impor-
tantly the loss of the entire DHFR-TS–coding sequence (Fig.
1B). We conclude that DHFR and TS activities are dispensable
in C. parvum.
C. parvum Lacking DHFR-TS Depends on Host-Supplied Thymidine.We
infected intestinal epithelial cell monolayers (human ileocecal
adenocarcinoma line HCT-8) with ΔDHFR-TS or the parental
WT parasites and quantified intracellular growth after 48 h of
culture. Both strains proliferated normally, but we noted that
growth of ΔDHFR-TS was enhanced when the medium was for-
tified with 10 μM thymidine (Fig. 1D). This suggests that the
parasite can forgo its own synthesis if thymidine is provided by the
host (see Fig. 1C for a schematic overview of thymidine metabo-
lism in host and parasite). To test this further, we examined the
growth of both strains in the presence of methotrexate (MTX), a
potent inhibitor of mammalian dihydrofolate reductase that blocks
host thymidine monophosphate (TMP) synthesis by starving the
reaction for reduced folate (15). Growth of ΔDHFR-TS parasites
was ablated under these conditions but could be fully rescued by
providing excess thymidine in the medium. Methotrexate treat-
ment was conducted at a commonly used dosage range (15) and
treatment had no effect on growth of WT parasites in the presence
or absence of thymidine. We conclude that DHFR-TS and TK
provide C. parvum with redundant routes to TMP and loss of either
enzyme renders the parasite hypersensitive to inhibition of the
other. Our experiments do not formally distinguish rescue of
the mutant by uptake of host-derived thymidine or TMP. How-
ever, our previous experiments demonstrated that ΔTK parasite
strains can no longer be labeled with 5-ethynyl-2′-deoxyuridine
(EdU), a thymidine analog (10). Thus, the parasite cannot take up
thymidine/EdU nucleotides from the host cell.
C. parvum Inosine Monophosphate Dehydrogenase Is Dispensable.
While pyrimidine synthesis is redundant in C. parvum, genome
analysis predicts a nonredundant and highly streamlined pathway
for purine nucleotide synthesis based on uptake and phosphory-
lation of adenosine to AMP (6, 14), followed by 3 further steps
leading ultimately to the production of guanosine monophosphate.
Inosine monophosphate dehydrogenase is the penultimate step in
this pathway (see Fig. 3A). C. parvum IMPDH appears to be a
particularly attractive potential drug target due to its evolutionary
origin through horizontal gene transfer from bacteria, because it is
the rate-limiting step in this pathway, and because it is clinically
validated in a variety of diseases (14, 16–18). CpIMPDH-selective
inhibitors were identified via high-throughput screening (18), and
subsequent medicinal chemistry optimization increased the po-
tency of enzyme inhibition by factors of 103 to 104. However, this
improvement resulted in only modest improvement of antipara-
sitic activity (18–22). In contrast, a T. gondii strain engineered to
depend on C. parvum IMPDH (12) showed pronounced suscep-
tibility to these compounds in culture that correlated with potency
of enzyme inhibition (Fig. 2A). This disparity could reflect differ-
ences in compound uptake or host cell metabolism, or unforeseen
differences in the purine salvage pathways of the 2 parasites.
To evaluate the importance of IMPDH directly in C. parvum,
we attempted to ablate the IMPDH gene. We used a modified
protocol employing a repair cassette generated by PCR featuring
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Fig. 1. Genetic ablation of C. parvum dihydrofolate reductase-thymidylate
synthase. (A) Schematic map of the locus of C. parvum DHFR-TS replaced by
homologous recombination with the Nluc-Neo marker conferring resistance
to paromomycin. CDS, coding sequence; gRNA, guide RNA. (B) PCR mapping
of WT and ablated locus (ΔDHFR-TS) -producing amplicons illustrated in A.
(C) Highly simplified metabolic map of host and parasite thymidine mono-
phosphate (TMP) synthesis. Both can synthesize TMP from UMP, or salvage
thymidine. (D) Parasite growth in HCT-8 cells over 48 h measured using an
image-based assay using VVL staining (12) arbitrarily set to 100% for each
strain to the growth observed in normal culture medium. Media were sup-
plemented with 10 μM thymidine (+thy), 1 μMmethotrexate (+MTX), or both.
n = 6; error bars show SD. Note that WT growth (blue) remains unchanged
while growth of ΔDHFR-TS (red) is significantly impacted by manipulation of
host cell thymidine levels, suggesting that the mutant relies on import of
thymidine from the host. Significance was determined using a 1-way ANOVA
with Tukey’s multiple comparisons test (**P < 0.01, ****P < 0.0001).
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only 50 bp of homologous upstream and downstream sequence to
target the locus (Fig. 2B). These sequences were introduced using
synthetic oligonucleotides, avoiding the need for plasmid cloning.
Luciferase-expressing parasites readily emerged after mice were in-
fected with transfected sporozoites. Transgenic parasites showed in-
fection and growth in multiple subsequent passages (Fig. 2C) and
mutant parasites showed no obvious growth defect in mice or HCT-8
cells. PCR mapping demonstrated insertion of the marker cassette
into the locus and loss of the IMPDH-coding sequence (Fig. 2D).
We considered that the locus might carry multiple copies of
the gene or might have undergone duplication or rearrangement
in a way that would preserve IMPDH at a different location in
the genome. We performed whole-genome sequencing of the
ΔIMPDH strain and determined it to be >99% identical to the
published genome for the C. parvum IOWA strain. Genomic
alignment of the ΔIMPDH strain demonstrated ablation of the
locus consistent with the PCR results and found no evidence for
additional sequences encoding IMPDH in the genome of the
mutant strain (Fig. 2E). We conclude that IMPDH is not es-
sential for C. parvum growth in tissue culture or mice.
C. parvum Purine Salvage Can Be Ablated at Multiple Steps of the
Pathways. The finding that ΔIMPDH mutants are viable was
surprising, as loss of IMPDH should deprive the parasite of XMP
and subsequently the undoubtedly essential GTP (6, 9, 14). We
considered that the parasite may harbor a yet-to-be-described
enzyme that could synthesize XMP using an alternative mecha-
nism and thus sidestep the loss of IMPDH. To explore this hy-
pothesis, we focused on guanosine monophosphate synthase
(GMPS), the last enzyme in the pathway that converts XMP to
GMP (Fig. 3A). We targeted GMPS for genetic ablation, this
time introducing an additional yellow fluorescent protein (YFP)
reporter in the gene replacement cassette. Transgenic parasites
were obtained, they were fluorescent, showing insertion of the
marker (SI Appendix, Fig. S2 A and B), and PCR mapping
demonstrated loss of the GMPS-coding sequence (Fig. 3B and SI
Appendix, Fig. S2C). ΔGMPS parasites grew without apparent
defect in vitro and in vivo, mirroring the findings for ΔIMPDH.
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Fig. 2. Targeting of the C. parvum inosine monophosphate dehydrogenase
locus. (A) Comparison of the impact on parasite growth and enzyme inhibition
of multiple series of IMPDH inhibitors (each symbol represents one compound;
see Results for reference). Note that for T. gondii engineered to depend on C.
parvum IMPDH [HXGPRT deletion and IMPDH replacement (12)], potency of
compounds against the organism correlates with that of the recombinant en-
zyme over 4 orders of magnitude (r2 = 0.17, P < 0.0001); no correlation is ob-
served for C. parvum. (B) Modified targeting procedure using 50-bp flanking
sequences (gray). PCR products used to map the WT and insertion locus are la-
beled “A” to “D.” To further validate ablation, amplicon B produces a pattern
distinguishing WT and ΔIMPDH when treated with the restriction enzyme AgeI.
(C) NanoLuciferase activity was measured in the feces of mice infected with
transfected parasites. The emerging paromomycin-resistant parasites were
passed multiple times in animals, demonstrating the viability of the strain.
Samples were pooled from 4 to 6 mice in triplicate; error bars are SD. (D) PCR
mapping of WT and ablated locus (ΔIMPDH) -producing amplicons illustrated in
B. (E) WT and ΔIMPDH C. parvumwere subjected to whole-genome sequencing.
Individual sequence reads mapping to IMPDH and surrounding loci in ΔIMPDH
are shown. Note gene loss.
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Fig. 3. C. parvum tolerates loss of purine synthesis, which renders it de-
pendent on host-derived purine nucleotides. (A) Simplified schematic rep-
resentation of human host and C. parvum parasite purine metabolism. The
parasite purine salvage pathway is shown in blue; the enzymes and trans-
porter ablated in this study are indicated. The proposed parasite nucleotide
uptake pathway is highlighted in red. The host can synthesize purines de
novo or salvage different bases and nucleosides. Mycophenolic acid (MPA)
blocks all routes to GMP except guanine phosphoribosyltransferase (GPRT).
A, adenine; Ado, adenosine; G, guanine; H, hypoxanthine. *Note that it is
yet unknown whether the presumptive nucleotide transporter imports tri-
(as shown here), di-, monophosphates, or all of them. (B–D) GMPS, AK,
and AT can be ablated. PCR of WT and respective mutant strains dem-
onstrating loss of coding sequence. Please refer to SI Appendix, Figs. S2–
S4 for full details on the validation of these 3 deletion mutants including
mapping controls and whole-genome sequencing. NanoLuciferase mea-
surements (reported as relative luminescence units; RLUs) from mouse
feces showing that all strains are viable and readily infect mice. Samples
were pooled from 4 to 6 mice in triplicate; error bars are SD; represen-
tative graph from 1 of 3 biological repeats. (E ) C. parvumWT and ΔIMPDH
parasites were cocultured with human host cells and subjected to MPA
treatment over a range of concentrations (growth was measured by
luciferase assay). Note the hypersensitivity of ΔIMPDH at 1 μM (***P <
0.001). (F ) Growth of ΔIMPDH treated with MPA is rescued by addition of
guanine to the medium (***P < 0.001). (E and F ) Unpaired, 2-tailed t test
with Welch’s correction. n = 6; 1 of 3 biological repeats is shown; error
bars are SD.
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We next explored the importance of AMP synthesis in C.
parvum. In P. falciparum, AMP is synthesized from IMP by the
successive and essential activities of adenylosuccinate synthase
and adenylosuccinate lyase (23–25). T. gondii can synthesize AMP
following the same route from IMP or alternatively by phos-
phorylation of adenosine through adenosine kinase (AK) (26, 27).
The required adenosine is imported by a specific adenosine
transporter (AT) (28). The C. parvum genome does not encode
adenylosuccinate synthase or lyase, but homologs of the T. gondii
AK and AT are present (14, 26). Biochemical studies using
recombinant enzyme have demonstrated that C. parvum AK
phosphorylates adenosine to AMP (28). We targeted AK and AT
for ablation in C. parvum and found that both genes can be re-
moved without apparent detriment to the parasite (Fig. 3 C andD;
also see SI Appendix, Figs. S3 and S4 for full mapping and genome
sequencing). Thus, we conclude that adenosine salvage is not es-
sential. In total, we ablated the transporter and 3 of the 4 enzymes
of the annotated purine nucleotide pathway of C. parvum (the
fourth enzyme was not attempted). We conclude that this pathway
is dispensable for parasite growth.
Loss of IMPDH Sensitizes C. parvum to Inhibition of Host Purine
Synthesis. Like all living cells, the parasite needs a source of
ATP and GTP to thrive. How is this satisfied in the absence of
the salvage pathway? While it is possible that this parasite har-
bors novel enzymes and transporters that permit purine salvage
independent of the canonical pathway, we hypothesized that C.
parvummay be one of the rare intracellular pathogens capable of
stealing purine nucleotides from the cytoplasm of their host cell.
Transporters capable of this remarkable feat were first described
for Rickettsia (29). This model predicts that the purine synthesis
knockouts are reliant on nucleotide import from the host cell. To
test this, we investigated parasite growth in host cells treated with
mycophenolic acid (MPA), a potent inhibitor of human IMPDH.
In humans, IMPDH is crucial to obtain GMP through de novo
purine synthesis as well as for salvage of adenosine, adenine, or
hypoxanthine (30) (see the schematic in Fig. 3A). Cryptosporidium
IMPDH and human IMPDH are phylogenetically divergent (14,
17) and differences in their structure and kinetic mechanism render
the parasite enzyme 1,000-fold more resistant to MPA (Ki =
9.3 μM) when compared with the 2 human enzymes [Ki = 11 and
6 nM (31–35)]. We treated infected cultures with MPA over a range
of concentrations and measured parasite growth. We note that
MPA at these concentrations is routinely used to select transgenic
strains for the related parasite T. gondii (36). As predicted, WT
parasites were resistant to MPA treatment, but ΔIMPDH para-
sites were hypersensitized in a dose-dependent fashion, leading to
a full growth arrest at 1 μM (Fig. 3E; P value < 0.0001). Human
cells can circumvent a block in IMPDH through the activity of
guanine phosphoribosyltransferase (GPRT), an enzyme not pre-
sent in C. parvum (6, 14). We repeated the MPA treatment and
supplemented the medium with exogenous guanine, the sub-
strate of GPRT, up to 200 μM. Guanine complementation rescues
growth of the MPA-treated ΔIMPDHmutant in a dose-dependent
fashion (Fig. 3F; P value < 0.0001). We conclude that C. parvum
can import guanine nucleotides from host cells. In wild-type par-
asites, guanine nucleotide uptake is redundant with the parasite’s
own purine nucleotide pathway. However, mutants lacking purine
synthesis rely entirely on purine nucleotide import from the host.
Adenosine Analogs Trace Host Nucleotide Import into C. parvum. The
T. gondii adenosine kinase and adenosine transporter were ini-
tially discovered in genetic experiments selecting for resistance
to the prodrug adenine arabinoside (AraA) (26–28). T. gondii AK
loss-of-function mutants showed 50-fold resistance compared
with WT (37) and AT mutants no longer incorporated radiola-
beled adenosine (28). We have previously demonstrated that AraA
is a substrate for C. parvum AK and that growth of C. parvum is
susceptible to AraA in culture (14, 38). In contrast to T. gondii,
we found that loss of AK or AT produced only moderate resistance
to AraA (Fig. 4 A and B) of a 1.4- and 2.1-fold increase in the
EC50, respectively (across 3 independent biological experiments).
Sustained susceptibility suggests that AraA is phosphorylated
by the human host AK and then AraA nucleotide is imported by
the presumptive C. parvum purine nucleotide transporter. Al-
ternatively, AraA could poison the host cell and thus indirectly
affect parasite growth.
To distinguish between these 2 alternatives, we sought to build
a positive assay for purine nucleotide import using 7-deaza-7-
ethynyl-2′-deoxyadenosine (EdA), an adenosine analog. EdA is
activated by AK and incorporated into DNA, where it can be
labeled fluorescently using azide-alkyne click chemistry (39). In
T. gondii cultures pulsed for 12 h with 10 μM EdA, all parasite
nuclei incorporated EdA (red fluorescence, Fig. 4 D and E). This
labeling depends entirely on parasite AK, as the nuclei of T.
gondii ΔAK mutants do not label with EdA. We performed
comparable experiments with C. parvum and again noted robust
EdA labeling of parasite nuclei in WT parasites (Fig. 4 F and G).
In contrast to T. gondii, we found only moderate reduction of
EdA labeling the C. parvum ΔAK strain. We conclude that in
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Fig. 4. C. parvum imports adenosine nucleotides. (A and B) WT and ΔAK (A)
or ΔAT (B) parasites were grown in HCT-8 cells in the presence of different
concentrations of adenosine arabinoside (AraA) and growth was measured
by NanoLuciferase assay (WT: NanoLuciferase expression site integrated
adjacent to TK gene causing no gene disruption). Unpaired, 2-tailed t test
with Welch’s correction, ****P < 0.0001; 1 of 3 biological repeats is shown;
error bars are SD; (A) n = 12, (B) n = 6. (C) Schematic outline of nuclear EdA
labeling in T. gondii and C. parvum. (D and F) Cultures were infected with T.
gondii (D) or C. parvum (F) for 12 h and then incubated with 10 μM EdA for
12 h, followed by fixation and permeabilization. (Scale bars, 5 μm.) EdA was
labeled by click chemistry (red), DNA was stained with Hoechst (blue), and
parasites were detected using an antibody to SAG1 or using V. villosa lectin
(VVL; both green). Images shown were acquired by structured illumination
superresolution microscopy. (E and G) Quantification of EdA labeling (n =
100; 3 biological replicates; error bars show SD; ****P < 0.0001). T. gondii
but not C. parvum nuclear labeling with EdA is abolished in ΔAK.
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C. parvum, but not T. gondii, there are 2 pathways leading to
adenosine (and EdA) incorporation: one where adenosine is
activated by AK in the parasite cytoplasm, and a second path
where adenosine is activated by host AK in the host cell cyto-
plasm followed by import of an EdA nucleotide into the parasite.
Conclusion
We used CRISPR/Cas9–driven genetic engineering of C. parvum
to ablate multiple genes involved in nucleotide metabolism,
pathways that were widely presumed to be critical for parasite
survival. Remarkably, these strains were viable. While nucleotide
synthesis has proven an excellent target for antimicrobial drugs
including for several Apicomplexa, the fact that these enzymes, in
particular DHFR-TS and IMPDH, can be ablated in Cryptospo-
ridium suggests that their chemical inhibition will likely not result
in effective treatments. These findings inspire renewed caution
when predicting the essentiality of presumptive drug targets from
metabolic maps solely derived by bioinformatic analysis.
It appears that the unique horizontal gene transfer of TK
provides C. parvum with an alternative route to TMP and thus
renders DHFR-TS dispensable. Alternatively, TMP import from
the host could satisfy this need and current evidence neither
proves nor refutes the existence of such a transporter. However,
parasites ablated for DHFR-TS (this study) or TK (10) are
similarly hypersensitive to the inhibition of the alternative en-
zyme. This argues that TMP must be synthesized in the parasite
and that therefore C. parvum likely lacks a mechanism to import
TMP. In contrast, C. parvum does not have known alternative
routes for purine synthesis. Nonetheless, the purine salvage en-
zymes are dispensable as demonstrated by multiple knockout
strains reported here. This is in stark contrast to T. gondii and
P. falciparum, where purine salvage is essential (25, 40) and a
firm requirement for tracer labeling (Fig. 4 D and E).
We cannot formally exclude the possibility that C. parvum may
harbor a novel, noncanonical purine salvage pathway that relies
on 2 new enzymes and a new transporter. However, such a
pathway does not readily explain our host-directed inhibitor and
fluorescent tracer experiments as well as uptake of purine nu-
cleotides from the host cell. Why would C. parvum import purine
but not pyrimidine nucleotides when both are required for DNA
and RNA synthesis? We propose energy parasitism as the po-
tential evolutionary root of this difference. Under this hypothe-
sis, C. parvum imports purine nucleotides because it relies on
the host cell ATP pool to satisfy its energy needs. Such trans-
porters were first described in Rickettsia (29) and Chlamydia
(41). Microsporidia, highly reduced intracellular fungal patho-
gens, were similarly shown to import purine nucleotides, and the
genes for these transporters appear to have been acquired by
horizontal gene transfer of the ancestral rickettsial genes (42) or
evolved from other members of the major facilitator superfamily
(43). Acquisition of ATP transport in these organisms is asso-
ciated with a significantly reduced energy metabolism. This is
most pronounced in the microsporidian Enterocytozoon bieneusi,
which lost its central carbon metabolism including glycolysis (44).
C. parvum energy metabolism has similarly sustained extensive
loss, most prominently the TCA cycle and oxidative phosphory-
lation (9). Transcriptional profiling of C. parvum life-cycle stages
revealed differential expression of the glycolytic pathway with
pronounced induction in female gametes and during sporogony
(8). Glycolysis may not be essential for intracellular growth, but
rather be required for extracellular parasite stages, including
oocyst persistence and the motility of invasive sporozoite and
merozoite stages. Further work is required to directly test the
importance of glycolysis and energy metabolism in different
phases of the parasite’s development.
What is the mechanism of C. parvum purine nucleotide im-
port? Earlier biochemical studies on P. falciparum suggested a
link between host and parasite ATP levels (45); however, no
specific transporter has been identified. Genome searches using
a variety of algorithms have so far failed to identify direct ho-
mologs of the nucleotide transporters identified in Microsporidia
in the genomes of Cryptosporidium species. Cryptosporidium may
have adapted a novel type of nucleotide transporter or, alter-
natively, coopted organellar transporters from its mitochondrion
or chloroplast. Further work is needed to discover the identity of
this purine nucleotide transporter.
Materials and Methods
Materials. Mycophenolic acid, vidarabine monohydrate (adenine arabino-
side), methotrexate, and thymidine were purchased from Sigma-Aldrich, and
guanine was purchased from Acros Organics.
C. parvum Mutant Construction. The DHFR-TS gene (cgd4_4460) was targeted
using a guide RNA consensus sequence located 373 bp upstream of the stop
codon. Regions of 980 bp upstream and 1,024 bp downstream of the coding
sequence were used to target replacement with the dual reporter–drug
selection cassette containing a NanoLuciferase-neomycin resistance fusion
protein driven by C. parvum regulatory elements (10). DNA constructs for
deletion of other enzymes were designed in a similar manner. The IMPDH
gene (cgd6_20) was targeted using a guide RNA 32 bp downstream of the
stop codon; 50 bp directly upstream and downstream of the coding se-
quence was used for recombination. GMPS (cgd5_4520) was targeted using a
guide RNA 294 bp downstream of the start codon and regions of homology
were derived from the 50 bp directly upstream of the guide sequence and
50 bp before the stop codon. This replaced 1,707 bp of the gene with the Nluc-
Neo selection cassette and a YFP reporter. Similarly, AK (cgd8_2370) was
targeted using a guide RNA 56 bp downstream of the start codon with
flanks from the first 50 bp of the coding region and a region 80 bp down-
stream of the stop codon, and AT (cgd2_310) was targeted for deletion using
a guide RNA 15 bp upstream of the stop codon and 50 bp directly upstream
and downstream of the ORF, replacing the entire coding sequence. All pri-
mers are listed in SI Appendix, Table S1.
C. parvum Mutant Isolation. C. parvum were purchased from Bunchgrass
Farms and sporozoites were electroporated with a plasmid containing Cas9
and the appropriate guide RNA along with a PCR product carrying the re-
placement cassette as detailed above. Transfected sporozoites were then
used to infect mice. Female IFN-gamma knockout mice (B6.129S7-Ifngtm1Ts/J;
JAX 002287) aged 6 to 8 wk were treated with an antibiotic mixture in the
drinking water for a week before infection, normal drinking water the day
of infection, and subsequently with paromomycin (10). For sporozoite in-
fection via gavage, each mouse was gavaged twice with 100 μL saturated
sodium bicarbonate in ultrapure water followed immediately by gavage with
transfected sporozoites in cold PBS. Fecal samples (pooled from the cage) were
collected and assayed as previously described (NanoGlo Luciferase Assay Kit
and GloMax luminometer; Promega) (10). Fecal DNA was isolated using the
Zymo Fecal DNA MicroPrep Kit (Zymogen) and PCR was performed to map
insertions. Transgenic oocysts were purified from fecal material as previously
described (10). All animal experiments were reviewed and approved by the
Institutional Animal Care and Use Committee of the University of Georgia
(A2016 01-028-Y1-A4) or the University of Pennsylvania (806292).
Whole-Genome Sequencing. Genomic DNA was isolated from 106 excysted
oocysts of WT, ΔIMPDH, ΔAK, or ΔAT using the Qiagen DNeasy Blood and
Tissue Kit. Libraries were prepared with Nextera XT Kits (Illumina) and 150-bp
paired end reads were collected on a MiSeq system (Illumina). Reads were
aligned to the reference genome for C. parvum IOWA (CryptoDB-43 as-
sembly, EuPathDB) using the Burrows–Wheeler Aligner (46) and sequence
variants were called using the Genome Analysis Toolkit haplotype caller
with a ploidy of 1 (47). Raw sequence files are available through the NCBI
(BioProject ID: PRJNA543286).
Cell Culture. Human ileocecal colorectal adenocarcinoma cells (HCT-8; ATCC
CCL-244) were cultured at 37 °C, 5% CO2 (10). T. gondii was grown in human
foreskin fibroblasts as described (14).
Luciferase Parasite Growth Assays. Bleach-treated oocysts (20,000 per well)
were cocultured with 70% confluent HCT-8 in 96-well cultures. For luciferase
assays, media were removed at 48 h and replaced with 100 μL lysis buffer
(NanoGlo Luciferase Assay System; Promega); plates were incubated at
37 °C, 5% CO2 for 15 min; 100 μL substrate mixture was added to each well
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and mixed; and finally, samples were transferred to white plates and read in
a luminometer. For image-based assays, samples were stained using Vicia
villosa lectin (VVL; Vector Labs) and DAPI; 4 × 4 tiled images were collected
at 40× using an automated microscope and parasites and host cell nuclei
were quantified using a macro written for ImageJ (48).
Nucleotide Labeling. At 12 h postinoculation, EdA was added (10 μM final
concentration), incubated for 12 h, and fixed. EdA incorporation was de-
tected using the Click-iT Plus EdU 594 Imaging Kit (Thermo Fisher). Coverslips
were stained with Hoechst (1 mg/mL) and VVL was conjugated to fluorescein
for C. parvum or a monoclonal antibody to SAG1 for T. gondii (1:1,000; gift
of Jean-Francois Dubrementz, University of Montpellier, Montpellier, France;
ΔAK T. gondii were a gift of David Roos, University of Pennsylvania). Images
were acquired on a DeltaVision OMX SR or on a Leica DM6000 at the Penn Vet
Imaging Core and processed using ImageJ.
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